Literature DB >> 2591149

One-shot high-dose pamidronate disodium (APD): effective, simple treatment for hypercalcaemia in haematological malignancy.

N Sawyer1, C Newstead, A Drummond, A Newland, J Cunningham.   

Abstract

Fifteen patients with haematological malignancy and hypercalcaemia (mean +/- SEM calcium 3.44 +/- 0.14 mmol/l) received pamidronate (1 mg/kg) by infusion on 17 occasions (two patients were retreated 2 and 6 months after the first dose). After 4 days the plasma calcium had fallen to 2.84 +/- 0.14 mmol/l (P less than 0.001; n = 17), and in 10/17 episodes was less than 2.6 mmol/l. The mean fall was 0.61 mmol/l (95% confidence intervals 0.49-0.72 mmol/l). By 7 days a further decrease to 2.53 +/- 0.10 mmol/l had occurred, continuing to 2.38 +/- 0.11 mmol/l after 14 days. Plasma phosphate fell from 1.18 +/- 0.16 to 0.74 +/- 0.07 mmol/l at 7 days (P less than 0.001; n = 12). In 9 of the 17 episodes plasma creatinine initially exceeded 120 mumol/l (four of these greater than 300 mumol/l). This did not impair the response to pamidronate and there was no significant change in plasma creatinine following treatment. A single large dose of pamidronate was a simple, well-tolerated and very reliable treatment for hypercalcaemia complicating haematological malignancy, irrespective of renal function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2591149     DOI: 10.1111/j.1365-2257.1989.tb00206.x

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN: 0141-9854


  2 in total

Review 1.  Comparative tolerability of drug therapies for hypercalcaemia of malignancy.

Authors:  N Zojer; A V Keck; M Pecherstorfer
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 2.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.